Stock of the Day - Daily Article
Written by MsEconometrica   
Saturday, 13 August 2011 08:06

ShangPharma Corporation (NYSE: SHP), Chaina-based holding company that operates as a biotechnology and pharmaceutical research and development outsourcing company. Shangpharma, headquartered in Shanghai-China, founded in 2002. Shangpharma is one of the largest Contract Research Organizations in China. ShangPharma Corporation provides high-quality, integrated services across the drug discovery and development process international and Chinese pharmaceutical and biotechnology company. These services consist of pharmaceutical development, preclinical development, discovery chemistry and discovery biology. Shangpharma Corporation has two subsidiaries: Shanghai ChemPartner (founded in 2003) and Chengdu Chempartner (was founded in 2006 in Chengdu). On 10th June 2011, ShangPharma announced in the top ten companies at the Fourth Annual China International Service Outsourcing Cooperation Conference.

Shangpharma Corporation has a market cap of $175.22 million. SHP has a P/E ratio of 12.21 and a forward P/E ratio of 8.32. Analysts expect SHP to have a 19.70% EPS growth in the next 5 years. For the first-quarter results of 2011, Shangpharma increased its revenues 26% to $24.8 million. ShangPharma reported gross profit of $8 million, representing a 15.3% increase from $6.9 million for the same quarter of 2010. ShangPharma expects net revenues to be approximately $111-$115 million at the end of the year 2011, representing a growth of approximately 25% million compared with the fiscal year 2010.

Last Updated on Saturday, 13 August 2011 11:51

Add comment

Comments are greatly appreciated.

Security code

. .